Hematology NewsNCCN guidelines highlight ‘complicated’ treatment for pediatric lymphomasJanuary 14, 2020B Cell LymphomaAggressive LymphomasPediatricsDLBCLLymphoma & Plasma Cell Disorders
Hematology NewsStudy halted; ‘hyperprogression’ seen with nivolumab for R/R PTCLDecember 9, 2019T Cell LymphomasAggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsCAR T-cell therapy found safe, effective for HIV-associated lymphomaSeptember 20, 2019B Cell LymphomaAggressive LymphomasLymphoma & Plasma Cell DisordersImmunotherapyDLBCLCellular Therapy
Hematology NewsBispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomasJune 21, 2019Aggressive LymphomasImmunotherapyLymphoma & Plasma Cell DisordersImmuno-oncologyLeukemia, Myelodysplasia, TransplantationB Cell LymphomaMantle Cell Lymphoma
Hematology News5F9 plus rituximab take a bite out of drug-resistant NHLJune 18, 2019Aggressive LymphomasIndolent LymphomaLymphoma & Plasma Cell DisordersB Cell LymphomaFollicular Lymphoma
Hematology News‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCLJune 17, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology NewsChemo-free Smart Start regimen looks promising in poor-prognosis DLBCLJune 7, 2019B Cell LymphomaAggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsSC-PEG comparable to pegaspargase in young ALL/LL patientsJune 1, 2019ALLAggressive LymphomasLeukemia, Myelodysplasia, Transplantation
Hematology NewsFDA opts not to ban textured breast implantsMay 3, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersPreventive Care
Hematology NewsMonitoring, early intervention key to CAR T safetyApril 24, 2019Cellular TherapyAggressive LymphomasImmunotherapyB Cell LymphomaTransplantationImmuno-oncologyLymphoma & Plasma Cell Disorders
Hematology NewsPowerful breast-implant testimony constrained by limited evidenceApril 4, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsUNITY-NHL: Interim findings show activity, tolerability of umbralisib for R/R MZLApril 2, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsFDA panel calls for changes to breast implant rupture screeningMarch 27, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsFDA panel leans toward more robust breast implant surveillanceMarch 26, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsTherapeutic dosing of busulfan helps reduce relapse in ASCTMarch 13, 2019TransplantationAggressive LymphomasLymphoma & Plasma Cell DisordersCellular Therapy
